Cargando…
Management of chemotherapy dose intensity for metastatic colorectal cancer
Chemotherapy dose intensity is a momentous parameter of antitumor clinical medication. In certain clinical trials, the actual application dose of the chemotherapeutic drugs is frequently different from the prescribed dose. The chemotherapy dose intensity completed in different trials is also variabl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931773/ https://www.ncbi.nlm.nih.gov/pubmed/35340557 http://dx.doi.org/10.3892/ol.2022.13261 |
_version_ | 1784671332517019648 |
---|---|
author | Chu, Xuelei Xue, Peng Zhu, Shijie |
author_facet | Chu, Xuelei Xue, Peng Zhu, Shijie |
author_sort | Chu, Xuelei |
collection | PubMed |
description | Chemotherapy dose intensity is a momentous parameter of antitumor clinical medication. In certain clinical trials, the actual application dose of the chemotherapeutic drugs is frequently different from the prescribed dose. The chemotherapy dose intensity completed in different trials is also variable, which has an impact on the treatment efficacy, disease prognosis and patient safety. When these agents are tested in the population, chemotherapy reduction and delay or failure to complete the planned cycle constantly occur due to age, performance status, adverse reactions and other reasons, resulting in the modification of the chemotherapy dose intensity. The present review analyzed the correlation between the chemotherapy dose intensity and the incidence of adverse reactions, the treatment efficacy and disease prognosis in clinical trials of metastatic colorectal cancer. Moreover, the clinical applications of chemotherapy dose intensity were discussed. Based on individual differences, the present review analyzed the clinical trials that examined the efficacy of the chemotherapy dose intensity in different patient populations. The conclusions suggested that different populations require a specific dose intensity to reduce treatment toxicity without affecting the curative effect. |
format | Online Article Text |
id | pubmed-8931773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-89317732022-03-25 Management of chemotherapy dose intensity for metastatic colorectal cancer Chu, Xuelei Xue, Peng Zhu, Shijie Oncol Lett Review Chemotherapy dose intensity is a momentous parameter of antitumor clinical medication. In certain clinical trials, the actual application dose of the chemotherapeutic drugs is frequently different from the prescribed dose. The chemotherapy dose intensity completed in different trials is also variable, which has an impact on the treatment efficacy, disease prognosis and patient safety. When these agents are tested in the population, chemotherapy reduction and delay or failure to complete the planned cycle constantly occur due to age, performance status, adverse reactions and other reasons, resulting in the modification of the chemotherapy dose intensity. The present review analyzed the correlation between the chemotherapy dose intensity and the incidence of adverse reactions, the treatment efficacy and disease prognosis in clinical trials of metastatic colorectal cancer. Moreover, the clinical applications of chemotherapy dose intensity were discussed. Based on individual differences, the present review analyzed the clinical trials that examined the efficacy of the chemotherapy dose intensity in different patient populations. The conclusions suggested that different populations require a specific dose intensity to reduce treatment toxicity without affecting the curative effect. D.A. Spandidos 2022-05 2022-03-11 /pmc/articles/PMC8931773/ /pubmed/35340557 http://dx.doi.org/10.3892/ol.2022.13261 Text en Copyright: © Chu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Review Chu, Xuelei Xue, Peng Zhu, Shijie Management of chemotherapy dose intensity for metastatic colorectal cancer |
title | Management of chemotherapy dose intensity for metastatic colorectal cancer |
title_full | Management of chemotherapy dose intensity for metastatic colorectal cancer |
title_fullStr | Management of chemotherapy dose intensity for metastatic colorectal cancer |
title_full_unstemmed | Management of chemotherapy dose intensity for metastatic colorectal cancer |
title_short | Management of chemotherapy dose intensity for metastatic colorectal cancer |
title_sort | management of chemotherapy dose intensity for metastatic colorectal cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931773/ https://www.ncbi.nlm.nih.gov/pubmed/35340557 http://dx.doi.org/10.3892/ol.2022.13261 |
work_keys_str_mv | AT chuxuelei managementofchemotherapydoseintensityformetastaticcolorectalcancer AT xuepeng managementofchemotherapydoseintensityformetastaticcolorectalcancer AT zhushijie managementofchemotherapydoseintensityformetastaticcolorectalcancer |